Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib
暂无分享,去创建一个
C. Antonescu | K. Manova | F. Giancotti | E. de Stanchina | D. Veach | B. Clarkson | P. Besmer | F. Rossi | Y. Yozgat
[1] M. Karin,et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.
[2] W. Gerald,et al. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. , 2009, The Journal of clinical investigation.
[3] Stephen K Burley,et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib , 2008, Proceedings of the National Academy of Sciences.
[4] S. Lim,et al. Distinct FAK-Src activation events promote α5β1 and α4β1 integrin-stimulated neuroblastoma cell motility , 2008, Oncogene.
[5] J. Parsons,et al. Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention , 2008, Clinical Cancer Research.
[6] J. Fletcher,et al. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance , 2007, Oncogene.
[7] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[8] Narasimhan P. Agaram,et al. Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor , 2007, Clinical Cancer Research.
[9] H. Joensuu. Second line therapies for the treatment of gastrointestinal stromal tumor , 2007, Current opinion in oncology.
[10] D. Schlaepfer,et al. Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.
[11] N. Socci,et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor , 2006, Proceedings of the National Academy of Sciences.
[12] G. Sauter,et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors , 2006, Modern Pathology.
[13] William Pao,et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[14] S. Shattil. Integrins and Src: dynamic duo of adhesion signaling. , 2005, Trends in cell biology.
[15] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[16] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[17] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[18] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[19] S. Knuutila,et al. Molecular targets for tumour progression in gastrointestinal stromal tumours , 2004, Gut.
[20] M. Ladanyi,et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] C. Antonescu,et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Parsons,et al. Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.
[23] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[24] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[25] P. Altevogt,et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins , 2001, The Journal of cell biology.
[26] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[27] L. Sobin,et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.
[28] F. Lindberg,et al. Thrombospondin-1 Acts Via IAP/CD47 to Synergize With Collagen in 2β1-Mediated Platelet Activation , 1999 .
[29] P. Besmer,et al. Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.
[30] Duc Hung Le,et al. SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.
[31] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[32] D. Cheresh,et al. A Single Immunoglobulin-like Domain of the Human Neural Cell Adhesion Molecule L1 Supports Adhesion by Multiple Vascular and Platelet Integrins , 1997, The Journal of cell biology.
[33] C. Deberry,et al. Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.
[34] N. S. Yee,et al. Differential roles of PI3‐kinase and Kit tyrosine 821 in Kit receptor‐mediated proliferation, survival and cell adhesion in mast cells. , 1995, The EMBO journal.
[35] S Torihashi,et al. Mutation of the proto‐oncogene c‐kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. , 1994, The Journal of physiology.
[36] H. Serve,et al. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.
[37] S. Nishikawa,et al. Requirement of c-kit for development of intestinal pacemaker system. , 1992, Development.
[38] T. Pawson,et al. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor , 1991, Molecular and cellular biology.
[39] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[40] Nils Cordes,et al. Signalling via integrins: implications for cell survival and anticancer strategies. , 2007, Biochimica et biophysica acta.
[41] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.